Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-13-2025

report update icon

Biophytis SA Income Statement 2011-2025 | BPTS

Annual Income Statement Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 549 M - - - - - - - - - -

Shares

- - 118 M - - - - - - - - - -

Historical Prices

0.33 1.43 4.64 - - - - - - - - - -

Net Income

- - -31.2 M -17.1 M -17.8 M -14 M -11.4 M -7.95 M -3.29 M -709 K -522 K - -

Operating Income

- - -26.8 M -13.9 M -15.7 M -13.9 M - - - - - - -

EBITDA

- - -26.8 M -13.9 M -15.7 M -13.9 M -9.7 M -7.77 M -3.12 M -659 K -468 K - -

General and Administrative Expenses

- - 7.15 M 4.02 M 4.6 M 4.35 M 2.86 M 2.82 M 2.07 M 373 K 396 K - -

All numbers in EUR currency

Quarterly Income Statement Biophytis SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Biophytis SA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.27 -2.43 % $ 1.22 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.75 1.61 % $ 788 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.26 -3.12 % $ 252 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.03 0.14 % $ 260 M israelIsrael
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 220.27 4.81 % $ 5 B danmarkDanmark
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.91 -5.01 % $ 18.7 M israelIsrael
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.28 -2.28 % $ 609 M israelIsrael
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.3 -3.51 % $ 7.94 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 89.78 -0.57 % $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.57 0.84 % $ 140 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.05 -7.06 % $ 496 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.34 2.59 % $ 14.7 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.29 -3.01 % $ 7.03 M chinaChina
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.01 -8.49 % $ 922 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 566.18 -2.56 % $ 42.9 B usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.16 0.47 % $ 399 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Biogen Biogen
BIIB
$ 174.42 1.11 % $ 25.4 B usaUSA
BioVie BioVie
BIVI
$ 1.42 -5.96 % $ 2.1 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.36 -2.09 % $ 1.76 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.63 -3.97 % $ 44.4 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.54 0.87 % $ 746 M usaUSA